CLINICAL IMPLICATIONS OF VARIABLE ANTIARRHYTHMIC DRUG-METABOLISM

被引：32

作者：

BUCHERT, E

WOOSLEY, RL

机构：

[1] Department of Pharmacology, Georgetown University Medical Center, Washington, DC, 20007-2195, 3900 Reservoir Road, NW

来源：

PHARMACOGENETICS | 1992年 / 2卷 / 01期

关键词：

D O I：

10.1097/00008571-199202000-00002

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Due to their narrow therapeutic indices, antiarrhythmic drugs have a great potential for adverse outcome. This is amplified by extreme inter-individual variability in their disposition and their pharmacological actions. Genetically determined inter-individual differences in metabolism account for a great deal of this variability. However, because of active metabolites, chirally-specific actions and chirally-specific metabolism, it is not possible to generalize about the outcome of phenotypic differences in the metabolism of a given drug. Careful study of these factors can enable physicians to understand the spectrum of potential responses to a drug. Newly developed molecular biology techniques now make it possible to determine the genotype for the CYP2D6 gene that controls metabolism of many antiarrhythmic drugs. This information, combined with a full understanding of the drugs' clinical pharmacology now makes it possible to predict the clinical outcome for drugs such as encainide, flecainide, mexiletine, propafenone and combinations of these drugs with quinidine.

引用

页码：2 / 11

页数：10

共 62 条

[1] Barbey J.T., Thompson K.A., Echt D.S., Woosley R.L., Roden D.M., Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl en- cainide and 3-methoxy-O-desmethyl encainide in man, Circulation, 77, pp. 380-391, (1988)
[2] Blomgren S.E., Condemi J.J., Vaughan J.H., Procainamide-induced lupus erythematosus-clinical and laboratory observations, Am J Med, 52, pp. 338-348, (1972)
[3] Broly F., Gaidigk A., Heim M., Eichelbaum M., Mariko K., Meyer U.A., Debrisoquine hydroxylase genotype and phenotype, DNA Cell Biol, 10, pp. 545-558, (1991)
[4] Broly F., Vandamme N., Caron J., Libersa C., Lhermitte M., Singledose quinidine treatment inhibits mexiletine oxidation in extensive metabolizers of debrisoquine, Life Sci, 48, (1991)
[5] Broly F., Vandamme N., Libersa C., Lhermitte M., The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation, Br J Clin Pharmacol, 32, pp. 459-466, (1991)
[6] Carey E.L., Duff H.J., Roden D.M., Primm R.K., Wilkinson G.R., Wang T., Oates J.A., Woosley R.L., Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals, J Clin Invest, 73, pp. 539-547, (1984)
[7] Carr R.K., Woosley R.L., Oates J.A., Simultaneous quantification of procainamide and N-acetylprocainamide with high performance liquid chromatography, J Chromatogr, 129, pp. 363-368, (1976)
[8] Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction, N Engl J Med, 321, pp. 406-412, (1989)
[9] Coates P.J., Dardenne A.J., Khan G., Kangro H.O., Slavin G., Simplified procedures for applying the polymerase chain reaction to routinely fixed paraffin wax sections, J Clin Pathol, 44, pp. 115-118, (1991)
[10] Connolly S.J., Kates R.E., Lebsack C.S., Harrison D.C., Winkle R.A., Clinical pharmacology of propafenone, Circulation, 68, pp. 589-596, (1983)

← 1 2 3 4 5 6 7 →